Obiltoxaximab (Anthim) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to heightened biodefense preparedness initiatives, government investment in anthrax countermeasures, approval of monoclonal antibody treatments, expansion of emergency medical response protocols, increasing global biosecurity awareness.

The growth in the forecast period can be attributed to expansion of national biodefense stockpiles, rising investments in next-generation antitoxin therapies, increased cross-border health security collaboration, growing focus on rapid deployment medical countermeasures, advancement in monoclonal antibody production technologies. Major trends in the forecast period include increasing strategic stockpiling of biodefense therapeutics, rising focus on rapid-response monoclonal antibodies, expansion of government-backed procurement programs, improved emergency preparedness frameworks, enhanced cold-chain distribution capabilities.

The rising incidence of zoonotic diseases is expected to drive the growth of the obiltoxaximab (Anthim) market in the coming years. Zoonotic diseases are infections that spread from animals to humans, either directly or through contact with animal products or vectors such as insects. The increasing incidence of these diseases is driven by factors such as greater human-wildlife interaction, urbanization, climate change, and global travel, which facilitate the transmission of infections from animals to humans. Obiltoxaximab (Anthim) is essential for addressing zoonotic threats, particularly anthrax, by providing targeted protection against this deadly infection. For example, in December 2023, the World Health Organization reported 684 suspected cases of anthrax across nine out of ten provinces in Zambia, with four confirmed deaths, reflecting a case mortality ratio of 0.6%. Therefore, the rising incidence of zoonotic diseases is driving the growth of the obiltoxaximab (Anthim) market.

The increase in biodefense budgets is also expected to propel the growth of the obiltoxaximab (Anthim) market. Biodefense budgets refer to government and organizational funding allocated for preparedness, prevention, and response to biological threats, including bioterrorism and emerging infectious diseases. Obiltoxaximab (Anthim) supports national biodefense strategies by offering a targeted therapy against inhalational anthrax, enhancing readiness for potential biological threats. For instance, in July 2023, the Council on Strategic Risks reported that the FY2024 U.S. budget proposed $400 million in new discretionary funding for BARDA/ASPR’s pandemic and biodefense preparedness efforts. Therefore, the rise in biodefense budgets is driving the growth of the obiltoxaximab (Anthim) market.

The increasing healthcare expenditure is further expected to drive the growth of the obiltoxaximab (Anthim) market. Healthcare expenditure encompasses total spending on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. Growth in healthcare expenditure is fueled by factors such as an aging population, rising chronic disease prevalence, and increased demand for healthcare services. Higher healthcare spending enables better access to advanced therapies such as obiltoxaximab (Anthim) by funding research, procurement, and deployment for the management of zoonotic diseases and bioterrorism threats. For example, in November 2025, the OECD reported that in 2024, member countries allocated an average of approximately 9.3% of their GDP to health. Therefore, the rising healthcare expenditure is propelling the growth of the obiltoxaximab (Anthim) market.

Major companies operating in the obiltoxaximab (anthim) market are Scorpius Holdings Inc.

North America was the largest region in the obiltoxaximab (anthim) market in 2025. The regions covered in the obiltoxaximab (anthim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the obiltoxaximab (anthim) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the obiltoxaximab market by increasing costs of imported biologic production materials, purification equipment, sterile packaging components, and cold-chain logistics systems required for monoclonal antibody storage and distribution. Government procurement agencies in North America and Europe are most affected due to reliance on imported biopharmaceutical inputs, while Asia-Pacific faces export-related cost pressures. These tariffs are raising overall stockpiling and readiness costs. However, they are also driving domestic biologics manufacturing, localized supply chain development, and strengthened national biodefense production capabilities.

The obiltoxaximab (anthim) market research report is one of a series of new reports that provides obiltoxaximab (anthim) market statistics, including obiltoxaximab (anthim) industry global market size, regional shares, competitors with a obiltoxaximab (anthim) market share, detailed obiltoxaximab (anthim) market segments, market trends and opportunities, and any further data you may need to thrive in the obiltoxaximab (anthim) industry. This obiltoxaximab (anthim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Obiltoxaximab (Anthim) is a monoclonal antibody used to treat inhalational anthrax caused by Bacillus anthracis. It works by binding to the protective antigen of the anthrax toxin, preventing the toxin from entering cells and causing damage. Obiltoxaximab is typically administered in combination with appropriate antibacterial medications and is approved for use in both adults and children.

The main distribution channels for Obiltoxaximab (Anthim) include distributors and online pharmacies. Distributors supply pharmaceuticals from manufacturers to retailers or healthcare providers. The medication is indicated for bioterrorism-related treatment, inhalational anthrax, cutaneous anthrax, and gastrointestinal anthrax and is used in hospitals and outpatient clinics.

The obiltoxaximab (anthim) market consists of sales of anthrax therapeutics, infectious disease treatments, emergency biodefense products and intravenous (iv) infusion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.